Dicerna Pharmaceuticals Stock Current Asset
Dicerna Pharmaceuticals fundamentals help investors to digest information that contributes to Dicerna Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Dicerna Stock. The fundamental analysis module provides a way to measure Dicerna Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dicerna Pharmaceuticals stock.
Dicerna |
Dicerna Pharmaceuticals Company Current Asset Analysis
Dicerna Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Dicerna Pharmaceuticals Current Asset | 59.38 M |
Most of Dicerna Pharmaceuticals' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dicerna Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, Dicerna Pharmaceuticals has a Current Asset of 59.38 M. This is 97.24% lower than that of the Healthcare sector and 94.4% lower than that of the Biotechnology industry. The current asset for all United States stocks is 99.36% higher than that of the company.
Dicerna Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dicerna Pharmaceuticals' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dicerna Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Dicerna Pharmaceuticals by comparing valuation metrics of similar companies.Dicerna Pharmaceuticals is currently under evaluation in current asset category among its peers.
Dicerna Fundamentals
| Return On Equity | -95.22 | |||
| Return On Asset | -10.43 | |||
| Profit Margin | (64.53) % | |||
| Operating Margin | (62.88) % | |||
| Current Valuation | 2.48 B | |||
| Shares Outstanding | 77.91 M | |||
| Shares Owned By Insiders | 7.43 % | |||
| Shares Owned By Institutions | 88.54 % | |||
| Number Of Shares Shorted | 4.77 M | |||
| Price To Earning | (1.58) X | |||
| Price To Book | 27.64 X | |||
| Price To Sales | 15.44 X | |||
| Revenue | 192.85 M | |||
| Gross Profit | (41.08 M) | |||
| EBITDA | (116.73 M) | |||
| Net Income | (124.44 M) | |||
| Cash And Equivalents | 565.51 M | |||
| Cash Per Share | 7.26 X | |||
| Total Debt | 64.42 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 2.46 X | |||
| Book Value Per Share | 1.38 X | |||
| Cash Flow From Operations | 21.05 M | |||
| Short Ratio | 0.84 X | |||
| Earnings Per Share | (1.63) X | |||
| Number Of Employees | 302 | |||
| Beta | 0.79 | |||
| Market Capitalization | 2.98 B | |||
| Total Asset | 62.95 M | |||
| Retained Earnings | (539.14 M) | |||
| Working Capital | 49.56 M | |||
| Current Asset | 59.38 M | |||
| Current Liabilities | 9.82 M | |||
| Z Score | 16.1 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Dicerna Stock
If you are still planning to invest in Dicerna Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dicerna Pharmaceuticals' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |